twipo #64 - interview with dr. lars wagner
It’s an exciting time to be part of the childhood cancer
research community, and this interview focuses on career advice for those
interested in childhood oncology and research.
The availability of genomic profiling of tumors, targeted agents and the
development of new immunotherapies are increasing the opportunities available
to patients today. This lively
discussion addresses the importance of preclinical data, predictive biomarker
studies and the measurement of responses, with specific references to Dr. Wagner’s
experience with studying irinotecan.
Dr. Wagner also answered questions about radiomics and how this imaging trend
can provide more insights for enhanced radiology reporting.
Please send questions and comments to TWiPO@solvingkidscancer.org